Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00390897
Status:
COMPLETED
Last Update Posted:
2008-11-27
First Post:
2006-10-20
Brief Title:
Glivec Imatinib Mesylate STI571 in Monotherapy Versus Glivec-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
Sponsor:
PETHEMA Foundation
Organization:
PETHEMA Foundation
Study Overview
Official Title:
Randomised Multicentre Phase IV Study to Compare Glivec Imatinib Mesylate STI571 in Monotherapy Versus Glivec in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the complete cytogenetic response rate in patients with newly-diagnosed chronic-phase chronic myeloid leukaemia treated with Glivec alone or in combination with interferon at low doses
Detailed Description:
Open prospective multicentre phase IV comparative and randomised study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03-0289 | None | None | None |